UnknownNCT05697107

Ripretinib in Chinese Patients With Advanced GIST: a Real World Study

Studying Gastrointestinal stromal tumor

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Peking University
Principal Investigator
Lin Shen, MD
Peking University
Intervention
Ripretinib Oral Tablet(drug)
Enrollment
308 target
Eligibility
18 years · All sexes
Timeline
2021 – 2023

Study locations (1)

Collaborators

First Affiliated Hospital, Sun Yat-Sen University · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sun Yat-sen University · Fudan University · Xiangya Hospital of Central South University · Fujian Medical University Union Hospital · The First Affiliated Hospital with Nanjing Medical University · First Affiliated Hospital of Zhejiang University · First Affiliated Hospital of Chongqing Medical University · RenJi Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05697107 on ClinicalTrials.gov

Other trials for Gastrointestinal stromal tumor

Additional recruiting or active studies for the same condition.

See all trials for Gastrointestinal stromal tumor →

← Back to all trials